作为治疗方法的奎尔丁纳米颗粒:药理作用和治疗中的潜在应用
1Zoology Department, Faculty of Science, Zagazig University, Sharkia, Egypt.
Biotechnologia
|January 23, 2025
概括
奎瑞纳米粒子增强药物输送和有效性,为癌症和阿尔茨海默氏症等疾病提供潜在的治疗方法. 它们的抗氧化和抗炎性质使它们在各种医疗应用中具有价值.
科学领域:
- 纳米技术纳米技术
- 药理学 药理学是指药理学的学科.
- 生物医学科学 生物医学科学
背景情况:
- 与传统Quercetin相比,Quercetin纳米粒子提供了更好的稳定性和生物可用性.
- 由于其多样化的治疗性质,它们是制药配方的组成部分.
研究的目的:
- 审查素纳米颗粒的药理动力学和生物活性.
- 突出它们对各种疾病的治疗潜力.
主要方法:
- 关于素纳米粒子研究的文献综述.
- 分析它们的特性,包括抗氧化,抗炎,抗癌和神经保护作用.
主要成果:
- 奎瑞纳米颗粒显示出抗癌,抗瘤,抗炎和抗糖尿病活性.
- 它们通过抑制乙胆酶在治疗阿尔茨海默病方面表现有前途.
- 有记录的抗氧化,抗癌,肝保护和细胞毒性作用.
结论:
- 夸斯纳米颗粒代表了一系列疾病的有希望的治疗策略.
- 它们的增强性质有助于在医学和药理学中开发新的治疗方法.
更多相关视频
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:49Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K